论文部分内容阅读
目的观察布地奈德福莫特罗粉吸入剂(信必可都保)联合复方甲氧那明治疗支气管哮喘前后的肺功能变化情况。方法 40例支气管哮喘急性发作的轻、中度患者,随机分为治疗组和对照组,各20例。治疗组应用信必可都保联合复方甲氧那明治疗;对照组仅应用信必可都保治疗。治疗4周后对比两组患者用药前后肺功能变化。结果治疗组患者较对照组相比,肺功能用力呼气量占用力肺活量比值(FEV1/FVC%)、一秒钟用力呼气量与用力肺活量比值(FEV1%)预计值差异具有统计学意义(P<0.01)。结论应用信必可都保联合复方甲氧那明治疗支气管哮喘,可明显改善患者肺功能水平,显著疗效,值得临床推广应用。
Objective To observe the changes of pulmonary function before and after bronchial asthma in combination with budesonide formoterol powder inhaler (Xinbikudubao) combined with metoprolol. Methods Forty mild and moderate patients with acute exacerbation of bronchial asthma were randomly divided into treatment group and control group, with 20 cases in each. The treatment group, the letter will be able to protect the combination of metoprolol treatment; control group, only the letter will be treated. Four weeks after treatment, the changes of pulmonary function in two groups before and after treatment were compared. Results Compared with control group, FEV1 / FVC%, forced expiratory volume and forced vital capacity (FEV1%) predictive value of the second treatment group were significantly different (P < P <0.01). Conclusions The combination of Xinbifuroduo combined with triamcinolone acetonide in the treatment of bronchial asthma can significantly improve the level of pulmonary function in patients with significant curative effect, worthy of clinical application.